A clinical formulation indicated for Antivirals. Facilitates the suppression of viral replication while supporting liver health during chronic infection management.
Indicated to address chronic Hepatitis C by targeting viral replication complexes to alleviate infection and support liver health in combination with other agents.
Mechanism of Action
Daclatasvir blocks the NS5A protein, a key building block for the Hepatitis C virus. By inhibiting this protein, the virus is unable to copy its RNA or assemble new virus particles, halting the infection.
Route of Administration
Oral
Onset Time
Steady state in 3 days
Duration
24 hours
Contraindications
Strong CYP3A inducers, Severe liver impairment (uncompensated), Hypersensitivity to daclatasvir
Severe Adverse Events
Severe bradycardia (with amiodarone and sofosbuvir), Hepatitis B reactivation, Liver failure, Severe allergic reactions
Common Side Effects
Fatigue, Mild headache
Uncommon Side Effects
Nausea, Diarrhea, Dizziness, Rash, Insomnia
Drug Interactions
Amiodarone, Rifampin, Carbamazepine, St. John's Wort, Ketoconazole, Ritonavir
Information for Natdac is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
